Skip to main content
SpringerLink
Log in

Schwerpunkt "Tumorrisikosyndrome"

Tumorrisikosyndrome: Erkennen - Untersuchen - Betreuen

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505(7483):302-8

  2. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23(2):276-92

  3. Seifert BA et al. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings. Clin Cancer Res. 2016;22(16):4087-94

  4. Schrader KA et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol. 2016;2(1):104-11

  5. Perne C et al. Seltene Tumoren als Leitsymptom hereditärer Tumorsyndrome. Pathologe. 2020;41(5):535-49

  6. Carta R et al. Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era. Front Oncol. 2020;10:566822

  7. Kratz CP t al. Predisposition to cancer in children and adolescents. Lancet Child Adolesc Health. 2021;5(2):142-54

  8. Northcott PA et al. Medulloblastoma. Nat Rev Dis Primers. 2019;5(1):11

  9. Ripperger T et al. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 2017;173(4):1017-37

  10. Medulloblastom im Kindes- und Jugendalter, S1-Leitlinie. 2018. AWMF Registernummer: 025 - 009; www.awmf.org/leitlinien/detail/ll/025-009.html, abgerufen am 6 April 2021

  11. Waszak SM et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19(6):785-98

  12. Accardo G et al. Genetics of medullary thyroid cancer: An overview. Int J Surg. 2017;41 Suppl 1:S2-S6

  13. Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016;375(11):1054-67

  14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Thyroid Cancer. Version 3.2020. Fort Washington (PA): National Comprehensive Cancer Network; 2021; https://www.nccn.org/professionals/physician_gls/default.aspx, abgerufen am 6 April 2021

  15. Wells SA Jr et al. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610

  16. Wasserman JD et al. Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017;23(13):e123-e132

  17. Luzón-Toro B et al. Influencers on Thyroid Cancer Onset: Molecular Genetic Basis. Genes (Basel). 2019;10(11):913

  18. Miasaki FY et al. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer. Genes (Basel). 2020;11(11):1364

  19. Capezzone M et al. Familial non-medullary thyroid cancer: a critical review. J Endocrinol Invest. 2020; www.doi.org/10.1007/s40618-020-01435-x

  20. Sippel RS et al. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg. 2007;31(5):924-33

  21. Hińcza K et al. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer. Genes (Basel). 2019;10(7):482

  22. Castro E et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-57

  23. Holter S et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2015;33(28):3124-9

  24. Pihlak R et al. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget. 2017;8(42):73240-57

  25. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.3, 2020,AWMF Registernummer:032-045OL; http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom, abgerufen am 6. April 2021

  26. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 4.0, 2020, AWMF-Registernummer: 032/035OL; https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom, abgerufen am 6. April 2021

  27. Goggins M et al. International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7-17

  28. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. Version 2.2021. Fort Washington (PA): National Comprehensive Cancer Network; 2021; https://www.nccn.org/professionals/physician_gls/default.aspx, abgerufen am 11. April 2021

  29. Weissman SM et al. Genetic testing by cancer site: ovary. Cancer J. 2012;18(4):320-7

  30. Kerlikowske K et al. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992;80(4):700-7

  31. www.ema.europa.eu/en/medicines/human/EPAR/lynparza, abgerufen am 6. April 2021

  32. www.kbv.de/html/1150_51478.php, abgerufen am 6. April 2021

  33. www.kbv.de/media/sp/EBM_2021-04-01_BA_551_BeeG_AMNOG_Lynparza_Olaparib.pdf, abgerufen am 6 April 2021

  34. Schneider M et al. Fanconi anaemia: genetics, molecular biology, and cancer - implications for clinical management in children and adults. Clin Genet. 2015;88(1):13-24

  35. Levy A, Lang AE. Ataxia-telangiectasia: A review of movement disorders, clinical features, and genotype correlations. Mov Disord. 2018;33(8):1238-47

  36. Keupp K et al. Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility. Mol Genet Genomic Med. 2019;7(9):e863

  37. de Alencar VTL et al. Inherited lung cancer: a review. Ecancermedicalscience. 2020;14:1008

  38. Musolf AM et al. Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent Studies. Genes (Basel). 2017;8(1):36

  39. Bisogno G et al. Pleuropulmonary blastoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer. 2021;e29045

  40. Robertson JC et al. DICER1 Syndrome: DICER1 Mutations in Rare Cancers. Cancers (Basel). 2018;10(5):143

  41. Blair VR et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386-e397

  42. Corso G et al. CDH1 germline mutations and hereditary lobular breast cancer. Fam Cancer. 2016;15(2):215-9

  43. Lerner BA et al. Genetic Gastric Cancer Risk Syndromes. Curr Treat Options Gastroenterol. 2020;18(4):604-15

  44. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):S3-Leitlinie Magenkarzinom,Langversion2.0, 2019AWMF Registernummer: 032/009OL; http://www.leitlinienprogramm-onkologie.de/leitlinien/magenkarzinom, abgerufen am 6. April 2021

  45. Krebs in Deutschland für 2015/2016. 12. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin. 2019

  46. Hampel H et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851-60

  47. Hampel H et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783-8

  48. Woods MO et al. The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. Gut. 2010;59(10):1369-77

  49. Ryan NAJ et al. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med. 2019;21(10):2167-80

  50. Hampel H et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66(15):7810-7

  51. Giardiello FM et al. US Multi-Society Task Force on Colorectal Cancer. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014;147(2):502-26

  52. Suerink M et al. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genet Med. 2019;21(12):2706-12

  53. Umar A et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-8

  54. Vasen HF et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453-6

  55. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1,2019, AWMF Registrierungsnummer: 021/007OL; http://www.leitlinienprogramm-onkologie.de/leitlinien/kolorektales-karzinom, abgerufen am 6. April 2021

  56. Niessen RC et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer. 2009;48(8):737-44

  57. Suerink M et al. Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019. Fam Cancer. 202;20(1):67-73

  58. Ripperger T, Schlegelberger B. Genetische Prädisposition für Krebserkrankungen im Kindesalter. Pathologe. 2018;39(Suppl 2):306-10

  59. Pathak SJ et al. EPCAM mutation update: Variants associated with congenital tufting enteropathy and Lynch syndrome. Hum Mutat. 2019;40(2):142-61

  60. Gaber A et al. Current View on EpCAM Structural Biology. Cells. 2020;9(6):1361

  61. Waller A et al. Familial Adenomatous Polyposis. J Pediatr Genet. 2016;5(2):78-83

  62. Knudsen AL et al. Attenuated familial adenomatous polyposis: results from an international collaborative study. Colorectal Dis. 2010;12(10 Online):e243-9

  63. Nielsen M et al. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol. 2011;79(1):1-16

  64. Knudsen AL et al. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer. 2003;2(1):43-55

  65. Win AK et al. Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. Int J Cancer. 2016;139(7):1557-63

  66. Lam AK, Saremi N. Cribriform-morular variant of papillary thyroid carcinoma: a distinctive type of thyroid cancer. Endocr Relat Cancer. 2017;24(4):R109-R121

  67. Park J et al. Multifocality in a Patient with Cribriform-Morular Variant of Papillary Thyroid Carcinoma Is an Important Clue for the Diagnosis of Familial Adenomatous Polyposis. Thyroid. 2019;29(11):1606-14

  68. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Colorectal. Version 1.2020. Fort Washington (PA): National Comprehensive Cancer Network; 2021; https://www.nccn.org/professionals/physician_gls/default.aspx, abgerufen am 6. April 2021

  69. Hruban RH et al. Update on familial pancreatic cancer. Adv Surg. 2010;44:293-311

  70. Golan T et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-27

  71. Holter S et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2015;33(28):3124-9

  72. Chen F et al. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Cancer Epidemiol Biomarkers Prev. 2019;28(7):1238-45

  73. Shindo K et al. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. J Clin Oncol. 2017;35(30):3382-90

  74. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Exokrines Pankreaskarzinom, Langversion 1.0, 2013, AWMF Registernummer: 032-010OL; http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html, abgerufen am 6 April 2021

  75. Frederiksen A et al. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases. J Clin Endocrinol Metab. 2019;104(9):3637-46

  76. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1-2):2-15

  77. Tirosh A et al. Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. JAMA Oncol. 2018;4(1):124-6

  78. Di Domenico et al. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017;24(9):R315-R334

  79. Dworakowska D, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer. 2009;16(1):45-58

  80. Geurts JL. Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2020;11(3):559-66

  81. Pea A et al. Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Rev Gastroenterol Hepatol. 2015;9(11):1407-19

  82. O'Shea T et al. When should genetic testing be performed in patients with neuroendocrine tumours? Rev Endocr Metab Disord. 2017;18(4):499-515

  83. Huang KL et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018;173(2):355-370.e14

  84. Ball MW, Shuch BM. Inherited kidney cancer syndromes. Curr Opin Urol. 201;29(4):334-43

  85. Carlo MI et al. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. Eur Urol. 2019;76(6):754-64

  86. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 3.2021. Fort Washington (PA): National Comprehensive Cancer Network; 2021; https://www.nccn.org/professionals/physician_gls/default.aspx, abgerufen am 6 April 2021

  87. Lui ST et al. Genetic Testing in Kidney Cancer Patients: Who, When, and How? Eur Urol Focus. 2019;5(6):973-6

  88. Pritchard CC et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375(5):443-53

  89. Robinson D et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-28

  90. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2.2021. Fort Washington (PA): National Comprehensive Cancer Network; 2021; https://www.nccn.org/professionals/physician_gls/default.aspx, abgerufen am 6. April 2021

  91. Schweizer MT et al. Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precis Oncol. 2019;3:PO.18.00327

  92. Isaacsson Velho P et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate. 2018;78(5):401-7

  93. Na R et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017;71(5):740-7

  94. Castro E et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019;37(6):490-503

  95. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019,AWMF Registernummer: 043/022OL; http://www.leitlinienprogramm-onkolo-gie.de/leitlinien/prostatakarzinom, abgerufen am 6. April 2021

  96. Giri VN et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020;38(24):2798-811

  97. Cheng HH et al. Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw. 2019;17(5):515-21

  98. Schierbeck J et al. Skin Cancer Associated Genodermatoses: A Literature Review. Acta Derm Venereol. 2019;99(4):360-69

  99. Cho HG et al. Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility. JCI Insight. 2018;3(15):e122744

  100. Arbeitsgemeinschaft Dermatologische Onkologie (ADO) der Deutschen Krebsgesellschaft und der Deutschen Dermatologischen Gesellschaft (DDG): S2k-Leitlinie "Basalzellkarzinom der Haut" (Aktualisierung 2017/2018), AWMF Register-Nr. 032-021. www.awmf.org/leitlinien/detail/ll/032-021.html, abgerufen am 6. April 2021

  101. Foulkes WD et al. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clin Cancer Res. 2017;23(12):e62-e67

  102. Read J et al. Melanoma genetics. J Med Genet. 2016;53(1):1-14

  103. Ransohoff KJ et al. Familial skin cancer syndromes: Increased melanoma risk. J Am Acad Dermatol. 2016;74(3):423-34; quiz 435-6

  104. Leachman SA et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 2017;36(1):77-90

  105. Rossi M et al. Familial Melanoma: Diagnostic and Management Implications. Dermatol Pract Concept. 2019;9(1):10-6

  106. Soura E et al. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol. 2016;74(3):395-407; quiz 408-10

  107. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2021. Fort Washington (PA): National Comprehensive Cancer Network; 2021; https://www.nccn.org/professionals/physician_gls/default.aspx, abgerufen am 6. April 2021

  108. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prävention von Hautkrebs, Langversion 2.0, 2021, AWMF Registernummer: 032/052OL; https://www.leitlinienprogramm-onkologie.de/leitlinien/hautkrebs-praevention, abgerufen am 6. April 2021

  109. Arber DA et al. The 2016 revision of the WHO classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405

  110. Rio-Machin A et al. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nat Commun. 2020;11(1):1044

  111. Polprasert C et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015;27(5):658-70

  112. Klco JM, Mullighan CG. Advances in germline predisposition to acute leukaemias and myeloid neoplasms. Nat Rev Cancer. 2021;21(2):122-37

  113. Ripperger T et al. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 2017;173(4):1017-37

  114. DiNardo CD et al. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016;16(7):417-428.e2

  115. DiNardo CD et al. Hereditary Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020;20 Suppl 1:S27-S29

  116. Furutani E, Shimamura A. Germline Genetic Predisposition to Hematologic Malignancy. J Clin Oncol. 2017;35(9):1018-1028

  117. DiNardo CD et al. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018;124(13):2704-13

  118. Bougeard G et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015;33(21):2345-52

  119. Frebourg T et al. European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28(10):1379-86

  120. Dutzmann CM et al. Ein Update zum Li-Fraumeni-Syndrom. Pathologe. 2019;40(6):592-9

  121. Brioude F et al. Overgrowth syndromes - clinical and molecular aspects and tumour risk. Nat Rev Endocrinol. 2019;15(5):299-311

  122. Satgé D et al. The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System. Front Immunol. 2018;9:3058

Download references

Author information

Authors and Affiliations

  1. AG Personalisierte Genomik, Institut für Humangenetik, Medizinische Hochschule Hannover, Hannover, Deutschland

    Ann-Cathrine Berking &  Anke Katharina Bergmann

Authors
  1. Ann-Cathrine Berking
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anke Katharina Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berking, AC., Bergmann, A. Tumorrisikosyndrome: Erkennen - Untersuchen - Betreuen. InFo Hämatol Onkol 24, 8–17 (2021). https://doi.org/10.1007/s15004-021-8651-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8651-5

Search

Navigation